+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Nicotine Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • PDF Icon


  • 60 Pages
  • February 2019
  • Region: Global
  • VPA Research
  • ID: 4749248
The global demand for Nicotine Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Nicotine Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Nicotine Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

Nicotine Addiction Report Description

The 2019 pipeline study on Nicotine Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Nicotine Addiction pipeline compounds.

The Nicotine Addiction pipeline guide presents information on all active drugs currently being developed for Nicotine Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Nicotine Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Nicotine Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Nicotine Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Nicotine Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Nicotine Addiction pipeline report includes
  • An overview of Nicotine Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.

  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

  • Phase wise count of Nicotine Addiction pipeline

  • Company wise list of Nicotine Addiction pipeline

  • Mechanism of Action wise Nicotine Addiction pipeline

For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

  • Current status of development

  • Drug overview

  • Mechanism of Action

  • Pre-clinical and Clinical Trials/Results

  • Company Overview and Recent Developments

Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations

  • Get clear understanding of the entire Nicotine Addiction pipeline, with details on active projects

  • Stay ahead of the competition through comprehensive knowledge of Nicotine Addiction pipeline progress

  • Get in detail information of each product with updated information on each project along with key milestones

  • Gain clear insights into companies participating in Nicotine Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

  • Get trial information for each pipeline product under development

  • Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Table of Contents

1.1 List of Tables1.2 List of Figures
2. Global Nicotine Addiction Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. Executive Summary
3.1 Nicotine Addiction Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Nicotine Addiction pipeline, H1- 2019
3.5 Mechanism of Action wise Nicotine Addiction Pipeline Candidates
4 Addex Therapeutics Ltd Nicotine Addiction Pipeline Details
4.1 Addex Therapeutics Ltd Business Profile
4.2 Addex Therapeutics Ltd Nicotine Addiction Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 Antidote Therapeutics Inc Nicotine Addiction Pipeline Details
5.1 Antidote Therapeutics Inc Business Profile
5.2 Antidote Therapeutics Inc Nicotine Addiction Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 Assuage Pharmaceuticals Inc Nicotine Addiction Pipeline Details
6.1 Assuage Pharmaceuticals Inc Business Profile
6.2 Assuage Pharmaceuticals Inc Nicotine Addiction Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 Astraea Therapeutics LLC Nicotine Addiction Pipeline Details
7.1 Astraea Therapeutics LLC Business Profile
7.2 Astraea Therapeutics LLC Nicotine Addiction Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 Camino Pharma LLC Nicotine Addiction Pipeline Details
8.1 Camino Pharma LLC Business Profile
8.2 Camino Pharma LLC Nicotine Addiction Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 Chronos Therapeutics Ltd Nicotine Addiction Pipeline Details
9.1 Chronos Therapeutics Ltd Business Profile
9.2 Chronos Therapeutics Ltd Nicotine Addiction Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 CV Sciences Inc Nicotine Addiction Pipeline Details
10.1 CV Sciences Inc Business Profile
10.2 CV Sciences Inc Nicotine Addiction Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 DemeRx Inc Nicotine Addiction Pipeline Details
11.1 DemeRx Inc Business Profile
11.2 DemeRx Inc Nicotine Addiction Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 Eolas Therapeutics Inc Nicotine Addiction Pipeline Details
12.1 Eolas Therapeutics Inc Business Profile
12.2 Eolas Therapeutics Inc Nicotine Addiction Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 Heptares Therapeutics Ltd Nicotine Addiction Pipeline Details
13.1 Heptares Therapeutics Ltd Business Profile
13.2 Heptares Therapeutics Ltd Nicotine Addiction Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 Indivior Plc Nicotine Addiction Pipeline Details
14.1 Indivior Plc Business Profile
14.2 Indivior Plc Nicotine Addiction Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 MAKScientific LLC Nicotine Addiction Pipeline Details
15.1 MAKScientific LLC Business Profile
15.2 MAKScientific LLC Nicotine Addiction Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16 Multimeric Biotherapeutics Inc Nicotine Addiction Pipeline Details
16.1 Multimeric Biotherapeutics Inc Business Profile
16.2 Multimeric Biotherapeutics Inc Nicotine Addiction Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17 Omeros Corp Nicotine Addiction Pipeline Details
17.1 Omeros Corp Business Profile
17.2 Omeros Corp Nicotine Addiction Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18 Savant HWP Inc Nicotine Addiction Pipeline Details
18.1 Savant HWP Inc Business Profile
18.2 Savant HWP Inc Nicotine Addiction Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19 Selecta Biosciences Nicotine Addiction Pipeline Details
19.1 Selecta Biosciences Business Profile
19.2 Selecta Biosciences Nicotine Addiction Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20. Latest Nicotine Addiction Drug Pipeline Developments, 2019
21. Appendix
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information

Companies Mentioned

  • Addex Therapeutics Ltd

  • Antidote Therapeutics Inc

  • Assuage Pharmaceuticals Inc

  • Astraea Therapeutics LLC

  • Camino Pharma LLC

  • Chronos Therapeutics Ltd

  • CV Sciences Inc

  • DemeRx Inc

  • Eolas Therapeutics Inc

  • Heptares Therapeutics Ltd

  • Indivior Plc

  • MAKScientific LLC

  • Multimeric Biotherapeutics Inc

  • Omeros Corp

  • Savant HWP Inc

  • Selecta Biosciences